Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Efectos adversos de los productos biológicos: un meta‐análisis en red y un resumen de revisiones Cochrane

Información

DOI:
https://doi.org/10.1002/14651858.CD008794.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 16 febrero 2011see what's new
Tipo:
  1. Overview
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Salud musculoesquelética

Copyright:
  1. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Jasvinder A Singh

    Correspondencia a: Department of Medicine, Birmingham VA Medical Center, Birmingham, USA

    [email protected]

  • George A Wells

    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada

  • Robin Christensen

    Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg og Frederiksberg, Copenhagen, Denmark

  • Elizabeth Tanjong Ghogomu

    Bruyère Research Institute, University of Ottawa, Ottawa, Canada

  • Lara J Maxwell

    Centre for Practice‐Changing Research (CPCR), Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital ‐ General Campus, Ottawa, Canada

  • John K MacDonald

    Cochrane IBD Group, Robarts Clinical Trials, London, Canada

  • Graziella Filippini

    Scientific Direction, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy

  • Nicole Skoetz

    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

  • Damian K Francis

    Epidemiology Research Unit, University of West Indies, Mona Kingston 7, Jamaica

  • Luciane C Lopes

    Sciences of Pharmaceutical Program, University of Sorocaba, São Paulo, Sorocaba, Brazil

  • Gordon H Guyatt

    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada

  • Jochen Schmitt

    Center for Evidence‐Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden, Dresden, Germany

  • Loredana La Mantia

    Unit of Neurorehabilitation ‐ Multiple Sclerosis Center, I.R.C.C.S. Santa Maria Nascente ‐ Fondazione Don Gnocchi, Milano, Italy

  • Tobias Weberschock

    Evidence‐Based Medicine Frankfurt, Institute of General Practice, Goethe University, Frankfurt, Germany

    Department of Dermatology, Venereology, and Allergology, J.W. Goethe‐University Hospital, Frankfurt, Germany

  • Juliana F Roos

    Dept of Clinical Pharmacy & Pharmacy Practice, Dubai Pharmacy College, Dubai, United Arab Emirates

  • Hendrik Siebert

    Cochrane Haematological Malignancies Group, University Hospital Cologne, Cologne, Germany

  • Sarah Hershan

    Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Australia

  • Chris Cameron

    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada

  • Michael PT Lunn

    Department of Neurology and MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK

  • Peter Tugwell

    Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada

    Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Canada

    Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada

  • Rachelle Buchbinder

    Monash Department of Clinical Epidemiology, Cabrini Hospital, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Malvern, Australia

Contributions of authors

Concept: JS, RC, GW, PT, RB

Title registration: JS, RB

Protocol draft: JS

Protocol editing: JS, GW, RC, ETG, NS, JKM, GF, LL, GG, ML, LM, JS, PT, RB

Title and abstract review: ETG, GF, JKM, PT, DF, Michelle Foote

Data abstraction: JS, ETG, NS, JKM, GF, LL, GG, ML, LM, JSchmitt, PT, RB, DF, TW, HS, SH, JR, RJ, Michelle Foote, Bharbhoor Dhaliwal

Data analysis: GW, RC, CC

Drafting the review: JS, RB, LM, EG

Editing and revising the review: JS, GW, RC, ETG, LM, NS, JKM, GF, LL, GG, ML, DF, J Schmitt, TW, PT, RB

Sources of support

Internal sources

  • Institute of Population Health, University of Ottawa, Canada.

    Logistic support

  • The Parker Institute: Musculoskeletal Statistics Unit, Copenhagen University Hospital, Denmark.

    The Oak Foundations provide support to the Parker Institute

External sources

  • Canadian Institutes of Health Research, Knowledge Synthesis Grant, Canada.

    Funding for logistics, organization and administrative support

  • National Institutes of Health Research, Cochrane Review Incentive Scheme 2009, UK.

    Funding for administrative support

Declarations of interest

JS: speaker honoraria from Abbott; research grants from AMGEN, Allergan, Takeda, Savient; consultant fee from Savient, URL Pharma, Novartis and Takeda.

GW: research grant and consultant fee from Bristol‐Myers Squibb; consultant fees from Abbott, Amgen, UCB; Data Safety Monitoring for Novartis. 

RC: has received consulting fees, honoraria, research or institutional support, educational grants, equipment, services or expenses from: Abbott, Astellas Pharma, Axellus, Bristol‐Myers Squibb, Cambridge Nutritional Foods, Centocor, DSM Nutritional Products, Hypo‐Safe, MSD, MundiPharma, NorPharma, Pharmavie, Pfizer, Roche, Sanofi‐Aventis, Scandinavian Clinical Nutrition.

ETG: none

NS: none

JKM: none

Filippini: none

DF: none

Lopes: none

La Mantia: none

Guyatt: in the last 5 years, Dr Guyatt has received grant funding from Pfizer, Lotte and John Hecht Foundation, Bristol‐Myers‐Squibb, and Astra Zeneca. Dr Guyatt has also received consultation fee from Up‐To‐Date and Eli Lilly Canada.  To our knowledge, none of these are conflicted with the subject matter of this submission.

Lunn: honoraria from Baxter in relation to advisory boards on the use of IVIG.

LM: none

Schmitt: research grant from Wyeth.

PT: grants/honoraria from Bristol Myers, Chiltern International, and UCB

RB: honoraria for the 3e initiative in 2010 funded by Abbott; Principal Investigator for the Australian Rheumatology Association Database (ARAD) ‐ The Australian Rheumatology Association has received unrestricted educational grants from Abbott, Amgen, Roche and Wyeth for ARAD.

JR: none

SH: none

TW: none

HS: none

RJ: none

CC: none

Acknowledgements

We thank Louise Falzon for developing the search strategies and assisting with full text article retrieval. We thank Michelle Fiander and Carolyn Wayne for assisting with full text article retrieval. We thank Michelle Foote, Bharbhoor Dhaliwal and Joseph Kundukulam for assisting with data extraction.

Version history

Published

Title

Stage

Authors

Version

2011 Feb 16

Adverse effects of biologics: a network meta‐analysis and Cochrane overview

Review

Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara J Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell, Rachelle Buchbinder

https://doi.org/10.1002/14651858.CD008794.pub2

2010 Oct 06

Adverse effects of biologics: a network meta‐analysis and Cochrane overview

Protocol

Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara Maxwell, Luciane C Lopes, John K MacDonald, Graziella Filippini, Damian Francis, Gordon H Guyatt, Michael PT Lunn, Jochen Schmitt, Nicole Skoetz, Peter Tugwell, Rachelle Buchbinder

https://doi.org/10.1002/14651858.CD008794